Сравнительная фармакологическая активность меглюмина акридонацетата и лизин акридонацетата при курсовом внутримышечном введении мышам на модели острой хламидийной инфекции

Abstract

According to the World Health Organization, as of 2020, annual infection with C. trachomatis, as register, 129 million people, with the highest incidence observed in group under the age of 25 years. Objective. The study of the pharmacological activity of meglumine acridone acetate and lysine acridone acetate, in the form of a solution for intramuscular administration, in a model of acute chlamydial infection with C. trachomatis in mice. Materials and methods. The studies were performed on 80 mice (male and female) of the DBA/2 line. Modeling of acute chlamydia in mice was carried out by intravenous administration of a live culture of C. trachomatis serovar D. A course (10 days) intramuscular administration of meglumine acridone acetate and lysine acridone acetate began on the 10th day of the experiment. Results. The study found that the administration of meglumine acridone acetate and lysine acridone acetate at doses of 46.4 mg/kg for 10 days in the acute phase of infection caused by C. trachomatis leads to positive dynamics in the clinical picture of the infectious process, weight gain in animals, and a decrease in the number of PCR-positive animals, the concentration of pro-inflammatory cytokines IL-1α and IL-6 and the values of the index of positivity of antibodies to C. trachomatis – IgM. Conclusion. The data obtained indicate the effectiveness of the use of meglumine acridone acetate and lysine acridone acetate in the treatment of infections caused by C. trachomatis. Key words: meglumine acridonacetate, lysine acridonacetate, acute chlamydial infection